On this week’s episode, Eric Schmidt, Paul Matteis, Sam Fazeli, and Brian Skorney begin with a recap of the week’s Sarepta news, covering their initial refusal then agreement to pause Elevidys shipments, if it can return to the market, the broader lessons for the biotech industry, and the communication breakdown between Sarepta and the FDA. Continuing with regulatory news, the group discusses the appointment of George Tidmarsh as the new CDER director and his role within FDA leadership. The conversation then turns to Replimune’s CRL for RP1 melanoma, Prasad’s likely influence in the rejection, and the impact on the investment community. In data news, the group overviews Alkermes’ positive Phase 1 data for its orexin 2 receptor agonist for type 1 narcolepsy, along with the safety controversy, and Abivax’s Phase 3 ulcerative colitis data and stock spike. Prime Medicine’s decision to reprice shares and strategies for better talent retention is also highlighted. The episode concludes with a brief overview of first-half 2025 licensing data, Roche earnings, and AstraZeneca’s $50 billion U.S. investment. *This episode aired on July 25, 2025.